Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blind, Phase 2 Study To Assess the Safety and Immunogenicity of CRV-101 Vaccine Head-To-Head With SHINGRIX® for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

NCT05304351 is registered in ClinicalTrials.gov with Curevo Inc as lead sponsor.

NCT NCT05304351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blind, Phase 2 Study To Assess the Safety and Immunogenicity of CRV-101 Vaccine Head-To-Head With SHINGRIX® for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Lead sponsor
Curevo Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 2, 2022
Completion date
March 6, 2032
Enrollment
1,516 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster, shingles